Categories
Change Password!
Reset Password!
Sphingosine-1-phosphate receptor modulators (S1PRMs) are widely utilized for treating relapsing multiple sclerosis (MS), with each agent illustrating distinct selectivity for S1P receptor subtypes.
Among S1PRMs for multiple sclerosis, fingolimod (1.25 mg) and ozanimod (1 mg) show the greatest efficiency, while siponimod (1.25 mg and 0.25 mg) demonstrates the best safety profile.
Sphingosine-1-phosphate receptor modulators (S1PRMs) are widely utilized for treating relapsing multiple sclerosis (MS), with each agent illustrating distinct selectivity for S1P receptor subtypes. By binding to G protein–coupled S1P receptors, they exert potent immunomodulatory effects, limiting the formation of new central nervous system (CNS) lesions and suppressing reactivation of existing ones. This study sought to assess the comparative efficacy and safety of different S1PRMs in MS management.
PubMed, Embase, and Cochrane Library were systematically searched for randomized controlled trials (RCTs) evaluating S1PRMs in MS. The primary outcomes were annualized relapse rate and incidence of adverse events. Standardized mean differences (SMDs) and odds ratios (ORs) were checked with 95% confidence intervals (CIs). Therapies were ranked using the Surface Under the Cumulative Ranking Curve (SUCRA). Risk of bias was monitored via the Cochrane RoB 2 tool.
From 1,750 screened records, 17 RCTs involving 16,006 volunteers were included. Fingolimod (1.25 mg) produced the greatest annualized relapse rate reduction (SMD = −0.4422; SUCRA = 92.65%), while ozanimod (1 mg) yielded the fewest new gadolinium-enhanced lesions (SMD = −0.6516; SUCRA = 86.38%). Siponimod (1.25 mg) was linked with the lowest rate of adverse events (OR = 0.4606; SUCRA = 93.20%). Most trials illustrated a low risk of bias.
Among S1PRMs, fingolimod and ozanimod illustrated the highest effectiveness, while siponimod showed the most favorable safety profile. Additional long-term research must validate these findings and examine their influence on patient-reported outcomes.
Annals of Clinical and Translational Neurology
The Comparative Effectiveness and Tolerability of Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta-Analysis of Randomized Controlled Trials
Faizan Shahzad et al.
Comments (0)